uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Goldman Sachs Downgrades uniQure BV (QURE) to Neutral, 'Awaiting clarity on path in Huntington's'
February 29, 2024 8:49 AM ESTGoldman Sachs analyst Salveen Richter downgraded uniQure BV (NASDAQ: QURE) from Buy to Neutral with a price target of $8.00 (from $63.00).
The analyst comments "QURE reported 4Q EPS and outlined intentions to gain clarity from the FDA on a potential approval pathway for the Ph1/2 gene therapy AMT-130 in Huntington's disease by YE24 (regulatory interactions will initiate in 2Q24). QURE disclosed that advancing AMT-130 into late-stage development... More
